2-氨基-2-甲基-丁酸甲酯盐酸盐 | 156032-14-3

• 物质功能分类: 化学试剂 - 有机试剂 - 酯类
• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: 2-氨基-2-甲基-丁酸甲酯盐酸盐
• 中文别名: DL-异缬氨酸甲酯盐酸盐
• 英文名称: HCl*H-DL-Iva-OMe
• 英文别名: 2-Amino-2-methyl-buttersaeuremethylester-hydrochlorid；methyl 2-amino-2-methylbutanoate hydrochloride；(±)-2-methyl-2-aminobutanoic acid methyl ester hydrochloride；2-amino-2-methyl-butyric acid methyl ester hydrochloride；(1-methoxy-2-methyl-1-oxobutan-2-yl)azanium;chloride
• CAS: 156032-14-3
• 化学式: C₆H₁₃NO₂*ClH
• mdl: MFCD06737779
• 分子量: 167.636
• InChiKey: HVPPPARGXDTDEY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.52
• 重原子数：
  10
• 可旋转键数：
  3
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.833
• 拓扑面积：
  52.3
• 氢给体数：
  2
• 氢受体数：
  3

安全信息

• 海关编码：
  2922499990

反应信息

• 作为反应物：
  描述：

  2-氨基-2-甲基-丁酸甲酯盐酸盐 在 palladium 10% on activated carbon 、 水 、 氢气 、 溶剂黄146 、 N,N-二异丙基乙胺 、 lithium hydroxide 作用下， 以 四氢呋喃 、 甲醇 、 二氯甲烷 、 氯仿 为溶剂， 20.0~200.0 ℃ 、101.33 kPa 条件下， 反应 8.0h， 生成 S-(-)-3-ethyl-3-methyl-2,5-dioxo-2,3,4,5-tetrahydro-1H-benzo[e][1,4]diazepine-7-sulfonyl chloride
  参考文献：
  名称：

  Identification and design of a novel series of MGAT2 inhibitors

  摘要：

  [Acyl CoA]monoacylglycerol acyltransferase 2 (MGAT2) is of interest as a target for therapeutic treatment of diabetes, obesity and other diseases which together constitute the metabolic syndrome. In this Letter we report our discovery and optimisation of a novel series of MGAT2 inhibitors. The development of the SAR of the series and a detailed discussion around some key parameters monitored and addressed during the lead generation phase will be given. The in vivo results from an oral lipid tolerance test (OLTT) using the MGAT2 inhibitor (S)-10, shows a significant reduction (68% inhibition relative to naive, p < 0.01) in plasma triacylglycerol (TAG) concentration. (C) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2013.02.084

文献信息

• Palladium-Catalyzed Direct Functionalization of 2-Aminobutanoic Acid Derivatives: Application of a Convenient and Versatile Auxiliary
  作者：Mengyang Fan、Dawei Ma

  DOI：10.1002/anie.201306583

  日期：2013.11.11

  New group on the block: 2‐Methoxyiminoacetyl is a readily available auxiliary for promoting palladium‐catalyzed γ arylation of C(sp3)H bonds. This auxiliary can be easily removed by either treatment with 1 n KOH at room temperature, or converted into a glycine moiety for peptide synthesis.

  上一个新的基团：2-甲氧基亚氨基乙酰基是促进钯催化C（sp 3）H键的γ芳基化的现成辅助剂。通过在室温下用1 n KOH处理，可以轻松除去该助剂，也可以将其 转化为用于肽合成的甘氨酸部分。
• Fungal Metabolites. IX. Synthesis of a Membrane-Modifying Peptide, Hypelcin A-III, from Hypocrea peltata.
  作者：Kouji MATSUURA、Akgul YESILADA、Akira IIDA、Yasuo NAGAOKA、Yoshihisa TAKAISHI、Tetsuro FUJITA

  DOI：10.1248/cpb.41.1955

  日期：——

  A membrane-modifying peptide antibiotic having uncoupling activity on rat liver mitochondria, hypelcin A-III, has been synthesized by assembling five peptide fragments via the N,N'-dicyclohexylcarbodiimide method. The synthesized hypelcin A-III was identical with the natural product.

  已经通过N，N′-二环己基碳二亚胺方法组装了五个肽片段，合成了对大鼠肝线粒体具有解偶联活性的膜修饰肽抗生素hypelcin A-III。合成的hypelcin A-III与天然产物相同。
• CXCR2 INHIBITORS
  申请人：HACHTEL Stephanie

  公开号：US20090227625A1

  公开（公告）日：2009-09-10

  The invention relates to compounds of the formula I in which R1, R2, X, A, B, Z and Y1 to Y4 have the meanings indicated in the claims, and/or a pharmaceutically acceptable salt and/or a prodrug thereof. Because of their properties as inhibitors of chemokine receptors, especially as CXCR2 inhibitors, the compounds of the formula I and the pharmaceutically acceptable salts and prodrugs thereof are suitable for the prevention and treatment of chemokine mediated diseases.

  本发明涉及公式I的化合物，其中R1、R2、X、A、B、Z和Y1到Y4具有所述权利要求中指示的含义，和/或其药学上可接受的盐和/或前药。由于它们作为趋化因子受体抑制剂的特性，尤其是作为CXCR2抑制剂，公式I的化合物及其药学上可接受的盐和前药适用于预防和治疗趋化因子介导的疾病。
• Quinazolinedione Chymase Inhibitors
  申请人：Guo Xin

  公开号：US20120122863A1

  公开（公告）日：2012-05-17

  Disclosed are small molecule inhibitors which are useful in treating various diseases and conditions involving Chymase.

  公开了小分子抑制剂，可用于治疗涉及Chymase的各种疾病和病况。
• CXCR2 inhibitors
  申请人：Hachtel Stephanie

  公开号：US08501981B2

  公开（公告）日：2013-08-06

  The invention relates to compounds of the formula I in which R1, R2, X, A, B, Z and Y1 to Y4 have the meanings indicated in the claims, and/or a pharmaceutically acceptable salt and/or a prodrug thereof. Because of their properties as inhibitors of chemokine receptors, especially as CXCR2 inhibitors, the compounds of the formula I and the pharmaceutically acceptable salts and prodrugs thereof are suitable for the prevention and treatment of chemokine mediated diseases.

  本发明涉及公式I的化合物，其中R1，R2，X，A，B，Z和Y1至Y4具有所述权利要求中指示的含义，和/或其药学上可接受的盐和/或前药。由于它们作为趋化因子受体抑制剂的特性，特别是作为CXCR2抑制剂，公式I的化合物和其药学上可接受的盐和前药适用于预防和治疗趋化因子介导的疾病。